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Abstract
Background: Tangshen Formula (TSF) is a traditional Chinese medicine for the treatment of diabetic kidney disease
(DKD). Liver-type fatty acid binding protein (L-FABP) is expressed in various tissues, including the kidney, where it
is known as urinary L-FABP. Other studies demonstrated that urinary L-FABP may be a useful biomarker for monitoring
DKD. This post-hoc analysis and cross-sectional study evaluated the changes in urinary L-FABP in DKD patients treated
with TSF and conventional medicine.
Methods: Post-hoc analysis was conducted on a multicenter, randomized, double-blind, placebo-controlled trial. A
total of 180 participants with DKD including 98 with microalbuminuria and 82 with macroalbuminuria were enrolled
in the original study. In addition to conventional treatment, 122 participants were randomly assigned to receive TSF and
58 to receive placebo. After 24-weeks of treatment, the intention-to-treat population in microalbuminuria stage was
56 in the TSF group and 25 in the placebo group, and in the macroalbuminuria stage 42 and 19, respectively. The
primary outcome in the original trial was urinary protein level. In the current study, urinary and plasma L-FABP levels
were measured in 30 microalbuminuria patients (15 in the TSF group and 15 in the placebo group) and
30 macroalbuminuria patients (15 in the TSF group and 15 in the placebo group). In addition, another
30 patients with normoalbuminuria (urinary albumin excretion rate (UAER) < 20 μg/min) were recruited for
the cross-sectional study.
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Results: (1) In microalbuminuria patients, UAER in the TSF group displayed a significant decrease after
24 weeks of treatment (P = 0.045). Levels of urinary L-FABP in the TSF group were markedly lower than in the
placebo group after 12 and 24 weeks (P = 0.004 and P = 0.047, respectively). (2) In macroalbuminuria patients,
24-h urinary protein levels decreased significantly compared with baseline in the TSF group at week 12 (P = 0.042) and
week 24 (P = 0.041). The TSF group showed a significant decrease in urinary L-FABP after 12 and 24 weeks (P = 0.036
and P = 0.046, respectively). (3) Levels of urinary L-FABP increased markedly, correlating with severity of DKD. L-FABP in
patients with normoalbuminuria, microalbuminuria, and macroalbuminuria were 5.9 (5.2, 7.8) μg/ml, 11.4 (6.8, 13.4) μg/
ml and 18.5 (10.9, 23.4) μg/ml, respectively (P = 0.000).
Conclusions: TSF combined with conventional therapy appeared to be effective in reducing urinary protein and
urinary L-FABP. Urinary L-FABP levels appear to be associated with the severity of DKD.
Trial registration: Chinese Clinical Trial Registry ChiCTR-TRC-10000843. Registered 15 April 2010.
Keywords: Chinese herbal medicine, Tangshen formula, Liver-fatty acid binding protein, Diabetic kidney disease
Background
Diabetic kidney disease (DKD) is a critical problem, affect-
ing approximately one third of people with diabetes mellitus
(DM) [1]. As the number of persons with DM increases
[2, 3], there has been a concomitant rise in DKD prevalence
with associated cardiovascular mortality and end-stage renal
disease (ESRD) [4]. DKD is also known as diabetic nephrop-
athy. It is characterized by a pathologic series of structural
abnormalities of all renal compartments, including glom-
erular and tubular basement membrane thickening, mesan-
gial expansion, interstitial inflammation, glomerular and
tubular hypertrophy, glomerulosclerosis, and tubulo-
interstitial fibrosis [5, 6], which eventually lead to renal
dysfunction [7].
It is now widely accepted that the tubulointerstitium is
closely involved in the pathogenesis of diabetic nephrop-
athy and its degree of fibrosis corresponds with the rate
of decline in kidney function [8, 9]. In the last decade,
clinical studies have demonstrated that increased urinary
liver-type fatty acid binding protein (L-FABP), which is
expressed in the proximal tubules in the human kidney, is
associated with the severity and clinical prognosis of DKD
[10]. For example, Kamijo et al. [11] found that urinary
L-FABP levels were progressively increased in patients
with normo-, micro-, or macroalbuminuria and further
increased in those with ESRD. After a 4-year follow-up,
urinary L-FABP levels in patients who showed DKD pro-
gression were higher than those without progression.
Thus, urinary L-FABP might be a suitable biomarker for
predicting and monitoring deterioration of renal function
in DKD. Furthermore, an accumulating number of
interventional studies have reported that urinary L-FABP
responds to renoprotective treatment [12–14].
Traditional Chinese Medicine (TCM) has been used for
millennia in China to treat a variety of diseases. Records
of using TCM to treat diabetes and its complications can
be found in ancient TCM literature. Even in modern
China, TCM is a primary or complementary therapy for
kidney disease [15, 16]. The traditional Chinese herbal
formula, Tangshen Formula (TSF), is composed of several
herbs and formulated based on empirical evidence. In our
previous studies, TSF showed a beneficial effect in attenu-
ating development of DKD [17–21]. In light of those
results, we conducted a multicenter randomized double-
blind placebo-controlled trial to further demonstrate the
efficacy and safety of TSF in treating DKD in persons with
type 2 diabetes [22]. Since L-FABP is a novel biomarker
for prognosis of DKD, we conducted this post-hoc analysis
to evaluate the effect of TSF on urinary and plasma L-
FABP in different DKD stages. In addition, we enrolled
another 30 sex- and age-matched patients with normoal-
buminuria to validate the clinical relevance of urinary L-
FABP levels at various stages of DKD.
Methods
Study design
This post-hoc analysis was conducted using data from a
previously published multicenter randomized double-blind
placebo-controlled study that investigated the efficacy and
safety of TSF in patients with type 2 diabetic kidney disease
(Chinese Clinical Trial Registry ChiCTR-TRC-10000843)
[22]. During that study, peripheral blood and urine samples
of the participants were collected at baseline, 12 weeks, and
24 weeks and had been in frozen storage at −80 °C. We
used these blood and urine samples to conduct this
post-hoc analysis on L-FABP. Details of the the original trial
design have been published previously [22]. The original
trial was approved by the ethics committee of the China-
Japan Friendship Hospital (No.2006–059). All participants
in the trial signed written informed consent documents.
Diagnostic standards
Type 2 diabetes was diagnosed based on the American
Diabetes Association guidelines (ADA; 2006) [23]. Diabetic
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kidney disease was diagnosed according to criteria of the
National Kidney Foundation Kidney Disease Outcomes
Quality Initiative (NKF-KDOQI; 2007) [24]. Participants
also underwent TCM diagnosis for their presenting syn-
drome (that is, TCM signs and symptoms). The pre-
dominant syndrome of qi-yin deficiency combined
with blood stasis was based on criteria established in
Clinical Research of New Investigational Drugs in
Traditional Chinese Medicine [25].
Study population
The inclusion and exclusion criteria have been described
previously [22] and are summarized here. Men and
women between the ages of 25 and 75 with type 2 diabetes
were eligible if they had urinary albumin excretion rate
(UAER) between 20 and 200 μg/min, and/or 24-h urinary
protein (24 h UP) between 0.5 and 2.0 g/d, and estimated
glomerular filtration rate (eGFR) between 60 ml/min and
130 ml/min, fasting blood glucose (FBG) ≤ 7.8 mmol/L,
and hemoglobin A1C ≤ 7.5 %; blood pressure < 140/
90 mmHg; and TCM syndrome was deficiency of both qi
and yin with blood stasis.
Patients were excluded if they had history of either kid-
ney disease or other disease with elevated urinary protein,
endocrine or metabolic disease, liver disease, cardiovascu-
lar disease within the past 3 months, or triglyceride (TG) >
10 mmol/L (>886 mg/dl). Patients taking glucocorticoster-
oids, thiazide diuretics, or niacin within the past 3 months
were also excluded as were pregnant or breastfeeding
women.
Randomization
A random allocation sequence was generated by computer
based on blocks of 6. Patients were randomly assigned to
either the TSF group (conventional treatments plus TSF) or
the placebo group (conventional treatments plus placebo)
in a 2:1 ratio and classified according to their different
stages of DKD (microalbuminuria or macroalbuminuria). A
total of 191 patients were screened, resulting in enrollment
of 180 participants, including 98 with microalbuminuria
and 82 with macroalbuminuria; 122 were randomly
assigned to receive TSF and 58 to receive placebo. After
24-weeks’ clinical observation, the intention-to-treat popu-
lation in microalbuminuria stage was comprised of 56 par-
ticipants in the TSF group and 25 in the placebo group,
while there were 42 and 19 participants in the TSF and pla-
cebo groups, respectively, in the macroalbuminuria stage.
Blood and urine samples were collected at baseline, 12 and
24 weeks and stored at −80 °C for further analyses. Since
only 15 macroalbuminuria participants in the placebo
group permitted their blood and urine to be collected, 30
sex- and age-matched microalbuminuria participants (15 in
the TSF group and 15 in the placebo group) and 30 sex-
and age-matched macroalbuminuria participants (15 in the
TSF group and 15 in the placebo group) were included to
assay their urinary and plasma L-FABP levels. In addition,
30 sex- and age-matched participants patients with nor-
moalbuminuria (UAER < 20 μg/min) were recruited from
China to Japan Friendship Hospital for a cross-sectional
study.
Treatment protocol
The treatment protocol has been described previously [22].
Based on ADA 2006 recommendations [23], antihyperten-
sive treatment, glycemic control, and antilipemic agents
were adopted as conventional treatment using open-label
drugs (calcium channel blockers, insulin, statins). All par-
ticipants received conventional treatment and participants
with albuminuria received either an angiotensin-converting
enzyme inhibitor or angiotensin receptor blocker agent.
After a 2-week run-in period with diet control and pro-
grammed daily exercise, TSF and placebo were initiated for
both groups with 8 g of granules dissolved in warm water,
taken twice daily for 24 weeks.
The Chinese herbal formula TSF consists of seven natural
herbs: astragalus root (Astragalus membranaceus (Fisch.)
Bunge); rehmannia root (Rehmannia glutinosa (Gaertn.)
DC.); notoginseng root (Panax notoginseng (Burk.) F.H.
Chen); winged burning bush twig (Euonymus alatus
(Thunb.) Sieb.); cornus fruit (Cornus officinalis Sieb. et
Zucc.); rhubarb root and rhizome (Rheum palmatum
L.); and bitter orange (Citrus aurantium L.). Main in-
gredients of the placebo were lactose, maltodextrin, and
artificial food coloring. Preparation of TSF and placebo
has been described previously [22]. TSF and placebo
granules were identical in packaging, appearance,
shape, size, and color.
Outcomes assessments
In the original trial, the primary outcome measure was urin-
ary protein level, which was assessed by UAER for partici-
pants with microalbuminuria and 24 h UP for participants
with macroalbuminuria. Secondary outcome measures were
renal function, including eGFR, Scr, and BUN, and lipid
profile, including TG, total cholesterol (TC), low density
lipoprotein (LDL), high density lipoprotein (HDL). Safety
indicators included alanine transaminase (ALT) and aspar-
tate aminotransferase (AST). In addition, FBG and A1C
were assessed. Blood and urine samples were collected from
participants and frozen at −80 °C at baseline, 12 and
24 weeks. For this post-hoc analysis, both urinary and
plasma L-FABP levels were measured using human L-FABP
ELISA kits (RapidBio Lab, Calabasas, CA, USA).
Statistical analysis
Statistical analysis was performed with SPSS 13.0 software
(IBM, Armonk, NY, USA). Normally distributed variables
were expressed as mean ± SD. Abnormally distributed
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variables were expressed as medians (interquartile range
(IQR)). To compare 2 normally distributed variables in the
same group, a paired t test was used. Student’s t test was
used for analyzing the difference of variables between 2
groups with normal distribution. In the 3 DKD groups,
normally distributed variables were compared using one-
way ANOVA, and all comparisons between abnormally
distributed parameters were performed with the Kruskal-
Wallis test. In TSF treatment trial, normality was assessed
using the Kolmogorov–Smirnov test, levels of abnormally
distributed urinary and plasma L-FABP were exponen-
tially- transformed (ln-transformed) before analysis, and if
data were normally distributed after transformation,
Student’s t test was used to compare differences between 2





Baseline demographic, clinical, and laboratory character-
istics of participants with microalbuminuria and macro-
albuminuria in the TSF and placebo groups were similar
(P > 0.05) (Table 1).
Effects of TSF on renal function indices and urinary and
plasma L-FABP levels in DKD patients with
microalbuminuria
There was no statistical differences in levels of Scr, BUN,
UAER, eGFR between the TSF group and the placebo
group in participants with microalbuminuria at baseline
(P = 0.136, P = 0.295, P = 0.975, P = 0.242, respectively),
12 weeks (P = 0.817, P = 0.080, P = 0.979, P = 0.713, re-
spectively) and 24 weeks (P = 0.343, P = 0.484, P = 0.385,
P = 0.697, respectively). However, after 12 and 24 weeks
of TSF treatment, UAER decreased markedly when com-
pared with that at baseline in the same group (P = 0.090
and P = 0.045), while in the placebo group, little or no
change was exhibited (P = 0.199 and P = 0.259). Levels of
Scr also declined and eGFR was increased over baseline in
the TSF group although without significant difference (at
12 weeks, P = 0.222 and P = 0.354, respectively; at 24 weeks,
P = 0.386 and P = 0.524, respectively). In the placebo
group, Scr and eGFR were unchanged (at 12 weeks,
P = 0.788, P = 0.860; at 24 weeks, P = 0.860, P = 0.713).
Levels of plasma L-FABP were abnormally distributed in the
TSF and placebo groups (P < 0.05), After ln-transformation,
levels of ln plasma L-FABP in each group were normally
distributed (P > 0.05). Compared with the placebo group,
levels of ln plasma L-FABP in the TSF group showed no
significant difference after 12 weeks or 24 weeks of
treatment (P = 0.190 at baseline, P = 0.131 at 12 weeks, and
P = 0.710 at 24 weeks, respectively) (Table 2). However,
urinary L-FABP levels in the TSF group were significantly
lower than levels in the placebo group after both12 weeks
and 24 weeks of treatment (8.2 ± 10.1 μg/ml compared with
8.5 ± 4.4 μg/ml at baseline, P = 0.940, 6.8 ± 2.9 μg/ml
compared with 11.1 ± 3.3 μg/ml at 12 weeks, P = 0.004 and
6.0 ± 3.0 μg/ml compared with 9.2 ± 4.9 μg/ml at 24 weeks,
P = 0.047, respectively) (Fig. 1).
Table 1 Baseline characterstics of participating diabetic kidney disease patients
Microalbuminuria Macroalbuminuria
TSF (n = 15) Placebo (n = 15) P Value TSF (n = 15) Placebo (n = 15) P Value
Age (yr) 56.1 ± 12.5 51.8 ± 8.5 .382 55.5 ± 8.2 58.0 ± 10.8 .522
Male/Female 9/6 7/8 .384 6/9 5/10 .400
BMI (kg/m2) 26.1 ± 3.7 26.0 ± 3.9 .950 25.9 ± 3.0 27.3 ± 2.9 .271
Blood pressure
Systolic (mmHg) 131.9 ± 7.8 128.3 ± 5.6 .259 130.1 ± 8.3 131.1 ± 9.3 .777
Diastolic (mmHg) 81.6 ± 6.4 76.2 ± 10.1 .142 78.6 ± 7.4 82.0 ± 4.9 .231
Laboratory variables
FBG (mmol/L) 6.7 ± 0.9 5.7 ± 1.0 .097 6.9 ± 1.5 6.8 ± 0.7 .752
A1C (%) 6.7 ± 0.6 6.5 ± 0.6 .065 6.7 ± 1.0 6.5 ± 1.3 .579
TG (mmol/L) 2.5 ± 1.6 2.2 ± 1.2 .617 2.7 ± 1.8 2.2 ± 1.0 .528
TC (mmol/L) 5.2 ± 0.9 4.9 ± 1.6 .532 5.2 ± 0.9 5.6 ± 1.2 .545
LDL (mmol/L) 3.0 ± 0.9 3.2 ± 1.4 .729 3.0 ± 1.2 3.8 ± 1.6 .293
HDL (mmol/L) 1.3 ± 0.6 1.0 ± 0.3 .091 1.3 ± 0.4 1.5 ± 0.3 .182
ALT (U/L) 26.2 ± 12.6 22.2 ± 9.1 .417 22.2 ± 8.7 22.9 ± 7.8 .835
AST (U/L) 22.4 ± 7.8 17.2 ± 5.5 .102 20.3 ± 5.7 22.5 ± 8.5 .443
Values expressed as mean ± SD
Abbreviations: ALT alanine aminotransferase, A1C glycosylated hemoglobin, AST aspartate aminotransferase, BMI body mass index, FBG fasting blood glucose, HDL
high density lipoprotein, LDL low density lipoprotein, TC total cholesterol, TG triglyceride
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Effects of TSF on renal function indices and urinary and
plasma L-FABP levels in DKD patients with macroalbuminuria
Levels of Scr, BUN, 24 h UP, eGFR were similar between
the two groups in participants with macroalbuminuria at
baseline (P = 0.594, P = 0.875, P = 0.996, P = 0.562, respect-
ively), 12 weeks (P = 0.144, P = 0.158, P = 0.628, P = 0.376,
respectively) and 24 weeks (P = 0.159, P = 0.090, P = 0.383,
P = 0.646, respectively). In the TSF group, 24 h UP
decreased significantly from 1.0 ± 0.7 g to 0.5 ± 0.5 g after
12 weeks (P = 0.042), remained at 0.5 ± 0.5 g after 24 weeks
(P = 0.041). However, in the placebo group, little change
was exhibited during the study period (P = 0.192 at 12 weeks
and P = 0.415 at 24 weeks). In addition, Scr, BUN and eGFR
remained unchanged compared to baseline in both
the TSF group (P = 0.776, P = 0.979 and P = 0.911 at
12 weeks; P = 0.849, P = 0.998 and P = 0.538 at
24 weeks, respectively) and placebo group (P = 0.495,
P = 0.119 and P = 0.664 at 12 weeks; P = 0.948, P = 0.113
and P = 0.914 at 24 weeks, respectively). Levels of plasma
and urinary L-FABP were abnormally distributed in
the TSF and placebo groups (P < 0.05). After ln-
transformation, ln plasma and urinary L-FABP were
normally distributed (P > 0.05). Ln plasma L-FABP
showed little change in both the TSF and placebo
groups (P = 0.643 at baseline, P = 0.328 at 12 weeks
and P = 0.402 at 24 weeks, Table 3). However, ln urin-
ary L-FABP decreased during 24 weeks of TSF treatment
and significantly increased during 24 weeks of placebo
treatment (baseline, TSF group 1.4 ± 0.6 μg/ml compared
with placebo group 1.1 ± 1.0 μg/ml, P = 0.455; 12 weeks,
TSF group 1.2 ± 0.3 μg/ml compared with placebo group
1.7 ± 0.3 μg/ml, P = 0.036; 24 weeks, TSF group 1.4 ±
0.5 μg/ml compared with placebo group 1.9 ± 0.5 μg/ml,
P = 0.046) (Fig. 2).
Cross-sectional study
Urinary L-FABP and Plasma L-FABP levels in DKD patients
Levels of urinary L-FABP in each DKD group differed
significantly from levels in the other groups and in-
creased markedly in accordance with the severity of
DKD (P = 0.000 between three groups; DKD patients with
microalbuminuria compared with DM patients with nor-
moalbuminuria P = 0.002; DKD patients with macroalbumi-
nuria compared with DM patients with normoalbuminuria
P = 0.000; DKD patients with macroalbuminuria compared
with DM patients with microalbuminuria P = 0.005,
Table 2 Effect of TSF and placebo on Scr, BUN, UAER, eGFR and
ln plasma L-FABP levels in patients with microalbuminuria
Parameters Groups Baseline Week 12 Week 24
UAER (μg/min) TSF 157.6 ± 72.9 115.9 ± 50.7 104.0 ± 32.4a
Placebo 158.6 ± 99.0 116.5 ± 69.7 121.8 ± 69.7
BUN (mmol/L) TSF 5.1 ± 1.2 5.6 ± 1.4 5.5 ± 1.4
Placebo 5.7 ± 1.6 6.6 ± 1.5 6.0 ± 2.3
Scr (μmol/L) TSF 73.5 ± 19.3 64.4 ± 19.7 67.6 ± 16.7
Placebo 60.8 ± 18.2 62.7 ± 19.8 61.9 ± 15.1
eGFR (ml/min/
1.73 m2)
TSF 102.7 ± 39.2 118.3 ± 49.4 113.9 ± 53.5
Placebo 128.3 ± 61.0 124.8 ± 45.2 121.0 ± 44.0
ln plasma L-FABP
(μg/ml)
TSF 1.0 ± 0.9 1.3 ± 0.8 1.2 ± 0.7
Placebo 1.4 ± 0.7 1.7 ± 0.6 1.1 ± 0.7
All values expressed as mean ± SD
a: P < 0.05 compared with baseline of the same group (Paired t test)
Abbreviations: BUN blood urea nitrogen, eGFR estimated glomerular filtration
rate, ln plasma L-FABP ln-transformed plasma liver-type fatty acid binding protein,
Scr serum creatinine, UAER urinary albumin excretion rate
Fig. 1 Effects of TSF on urinary L-FABP levels in microalbuminuria
patients during the 24-week treatment period. Values presented as
mean ± SE; *P= 0.004 and # P= 0.047 compared with the placebo group
at the same time point. L-FABP = liver-type fatty acid binding protein
Table 3 Effect of TSF and placebo on Scr, BUN, UAER, eGFR and
ln plasma L-FABP levels in patients with macroalbuminuria
Parameters Groups Baseline Week 12 Week 24
24 h UP (g/24 h) TSF 1.0 ± 0.7 0.5 ± 0.5a 0.5 ± 0.5a
Placebo 0.9 ± 0.6 0.6 ± 0.6 0.7 ± 0.7
BUN (mmol/L) TSF 6.0 ± 1.7 6.0 ± 1.7 6.0 ± 1.9
Placebo 6.1 ± 1.1 6.9 ± 1.6 7.2 ± 1.7
Scr (μmol/L) TSF 74.9 ± 20.7 72.6 ± 22.6 73.5 ± 18.9
Placebo 79.4 ± 18.2 84.0 ± 17.4 83.1 ± 16.4
eGFR (ml/min/1.73 m2) TSF 104.1 ± 32.8 102.7 ± 37.7 97.3 ± 25.8
Placebo 96.2 ± 30.0 91.3 ± 30.1 92.3 ± 32.2
ln plasma L-FABP
(μg/ml)
TSF 1.7 ± 1.0 1.3 ± 1.3 1.5 ± 0.9
Placebo 1.6 ± 1.2 0.8 ± 1.4 1.2 ± 1.0
All values expressed as mean ± SD
aP < 0.05 compared with baseline of the same group (Paired t test)
Abbreviations: BUN blood urea nitrogen, eGFR estimated glomerular filtration
rate, ln-serum L-FABP ln-transformed serum liver-type fatty acid binding protein,
Scr serum creatinine, UAER urinary albumin excretion rate
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respectively) (Table 4). However, plasma L-FABP
levels did not differ significantly between each DKD
group (P = 0.888).
Discussion
The renoprotective effects of the traditional Chinese
herbal medicine TSF have been described in other
reports [17, 21], including the original study [22] on
which this post-hoc analysis and cross-sectional study
were based. Results from the original study indicated
that TSF as an adjunct to conventional diabetes treat-
ments was more efficacious in lowering 24 h UP than
conventional treatments alone in patients with macro-
albuminuria [22]. Evidence from our previous studies
have revealed that TSF attenuates development of
diabetic nephropathy [17, 18, 22]. Specifically, TSF
improves renal impairment by decreasing accumulation
of extracellular matrix in the renal tissue by reducing ex-
pression of transforming growth factor-beta1 (TGF-β1)
and increasing expression of matrix metallopeptidase 9
[19]. We have also demonstrated that TSF can reduce
glomerulosclerotic and interstitial fibrotic indices and
decrease serum TC and 24 h UP [17]. In this post-hoc
analysis, we found that TSF decreased UP over the time
course in macroalbuminuria patients, but did not differ
from placebo. This phenomenon might be explained by
the small sample size, since there were only 15 partici-
pants in each group.
The renal protective mechanisms of individual herbs
in TSF have been discussed in numerous studies. Active
components in astragalus, rehmannia, rhubarb, corne-
lian cherry, and winged burning bush twig have been
found to reduce albuminuria, suppress activation of nu-
clear factor-kappaB, down-regulate TGF-β1 expression,
and decrease extracellular matrix accumulation [26–30].
In this post-hoc analysis and cross-sectional study, we
tested the hypothesis that TSF combined with conventional
treatment would lower urinary and serum L-FABP both in
micro- and macroalbuminuria patients. Our hypothesis
originated from results of other clinical studies that showed
urinary L-FABP was correlated with severity of tubulointer-
stitial injury, which suggested that urinary L-FABP is a
predictor for the deterioration of renal function in DKD
[10, 11]. L-FABP as an effective endogenous antioxidant is
important for free fatty acid (FFA) metabolism [31, 32].
When experimental mice were exposed to albumin-bound
FFAs, tubulointerstitial damage was more severe than mice
exposed to albumin alone, as unbound albumin is re-
absorbed in the proximal tubules [33]. Our previous study
showed that TSF has a lipid-lowering effect, suggesting that
TSF exerts a protective effect in the tubulointerstitium [17].
It is not clear whether urinary excretion of L-FABP is
correlated with urinary protein. Results from a prospect-
ive observational follow-up study showed that although
urinary L-FABP level was correlated with severity of
albuminuria in all stages of DKD, this was not the case for
a subgroup of patients with eGFR > 60 ml/min/1.73 m2
[11]. Therefore, in our study, the effect of TSF on urinary
L-FABP might be independent of albuminuria.
To date, albuminuria and eGFR are widely used as
markers of DKD progression. However, these tests are im-
precise because long before the onset of microalbuminuria
in diabetic patients, hemodynamic changes occur in the
glomeruli [34]. For example, results from the Developing
Education on Microalbuminuria for Awareness of Renal
and Cardiovascular Risk in Diabetes (DEMAND) study
showed that 20.5 % of diabetic patients with decreased
kidney function had normal albuminuria [35]. The Na-
tional Evaluation of the Frequency of Renal Impairment
cO-existing with NIDDM (NEFRON) study found that
Fig. 2 Effects of TSF on urinary L-FABP levels in macroalbuminuria
patients during the 24-week treatment period. Values presented as
mean ± SE; *P = .036 and # P = 0.046 compared with the placebo
group at the same time point. ln urinary L-FABP = ln-transformed
liver-type fatty acid binding protein






Median (IQR) Median (IQR)
DM patients with normoalbuminuria
(n = 30)
5.9 (5.2, 7.8) 4.4 (2.9,11.3)
DKD patients with microalbuminuria
(n = 30)
11.4 (6.7, 13.4)a 6.7 (3.4,11.4)
DKD patients with macroalbuminuria
(n = 30)
18.8 (10.9, 23.4)a,b 8.6 (2.5,12.4)
aP < 0.05 compared with the DM patients with normoalbuminuria
(Kruskal-Wallis test)
bP < 0.05 compared with the DKD patients with microalbuminuria
(Kruskal-Wallis test)
Abbreviations: IQR interquartile range, serum L-FABP serum liver-type fatty acid
binding protein, urinary L-FABP urinary liver-type fatty acid binding protein
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more than half (55 %) of type 2 diabetes patients with an
eGFR < 60 ml/min per 1.73 m2 had normoalbuminuria
[36]. In addition, estimated GFR is commonly used instead
of direct GFR measurement, which compromises accuracy
[37]. Thus, current tests to assess kidney function and
damage are inadequate and new biomarkers that can
monitor kidney function, injury and repair, and predict DKD
risk are needed. Indeed, L-FABP has been the focus of in-
tense study as a new biomarker for early diagnosis and pre-
diction of DKD risk [10, 11, 38]. Moreover, the Ministry of
Health, Labour and Welfare in Japan has approved urinary
L-FABP as a tubular biomarker for monitoring DKD [39].
In our study, urinary L-FABP levels increased with the
progression of DKD, similar to other reports such as by
Chou and colleagues [40]. However, we did not test
urinary creatinine level, and as such were unable to use
it to calibrate urinary L-FABP levels, which might be
affected by the concentration of the urine samples. In
addition to the kidney, L-FABP is expressed in the liver.
L-FABP derived from the liver is released into the
circulation, filtered through glomeruli and taken up by
proximal tubules [41]. But, in our study no difference in
plasma L-FABP levels were observed among participants
in different stages of DKD, suggesting that plasma L-
FABP levels do not affect urinary L-FABP levels.
Our study revealed that TSF could reduce the urinary L-
FABP level in DKD patients, and has the same trend as
urinary protein. Furthermore, since urinary L-FABP levels
have been found to be significantly correlated with urinary
8-OHdG levels [12], our finding suggests that the beneficial
effect of TSF in DKD is partly mediated by reduction of
oxidative stress.
Our study has limitations. Healthy participants were not
included. As such, differences in urinary L-FABP levels be-
tween DKD patients and healthy individuals were not eval-
uated. In addition, as a tubular marker, urinary L-FABP
does not predict a decline in GFR in overt DKD patients
[42]. Since the progression of DKD is defined as an in-
crease in urinary albumin concentration, it may be difficult
to determine the potency of urinary L-FABP for diagnosis
or prediction of progression of DKD. Further research is
needed to validate the reference values of urinary L-FABP
for distinguishing different stages of DKD, as well as the
possible mechanism by which TSF affects urinary L-FABP.
Conclusions
In summary, results of this post-hoc analysis and cross-
sectional study further extend observations that the
traditional Chinese medicine Tangshen Formula appears to
be a promising treatment for DKD. Moreover, urinary L-
FABP may be a useful biomarker for predicting the pro-
gression of DKD. Further studies are needed to confirm its
potential for clinical application.
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